Remibrutinib

Remibrutinib

Remibrutinib

Chemical compound

Remibrutinib is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria.[1][2] In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.[3]

Quick Facts Clinical data, ATC code ...

References

  1. [1]
    Maurer, Marcus; Berger, William; Giménez-Arnau, Ana; Hayama, Koremasa; Jain, Vipul; Reich, Adam; Haemmerle, Sibylle; Lheritier, Karine; Walsh, Pauline; Xia, Summer; Storim, Julian (December 2022). "Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria". The Journal of Allergy and Clinical Immunology. 150 (6): 1498–1506.e2. doi:10.1016/j.jaci.2022.08.027. hdl:10230/55511. ISSN 1097-6825. PMID 36096203.
  2. [2]
    Maurer, Marcus; Giménez-Arnau, Ana; Jain, Vipul; Tillinghast, Jeffrey; Tolcachier, Alberto; Nigen, Simon; Hayam, Koremasa; Lheritier, Karine; Walsh, Pauline; Haemmerle, Sibylle (February 2022). "Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria". Journal of Allergy and Clinical Immunology. 149 (2): AB179. doi:10.1016/j.jaci.2021.12.589. S2CID 246522006.
  3. [3]
    "Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2". Novartis. Retrieved 11 November 2023.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Remibrutinib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.